Best Earnings Power Value Drug Manufacturers - Specialty & Generic Stocks 2026

Top Drug Manufacturers - Specialty & Generic stocks by Earnings Power Value (EPV) upside in 2026. Greenwald-framework valuation updated daily from SEC filings.

44 stocks analyzed Updated 2026-05-29
# Ticker Company QOC Price EPV Upside
1 EBS Emergent BioSolutions Inc. 8.3 $9.18 +468.1%
2 OGI Organigram Global Inc. 5.6 $1.14 +67.7%
3 PCRX Pacira BioSciences, Inc. 8.7 $23.68 +41.8%
4 TAK Takeda Pharmaceutical Company L 7.4 $16.15 +34.7%
5 SIGA SIGA Technologies Inc. 10.0 $4.76 +4.3%
6 AKBA Akebia Therapeutics, Inc. 6.8 $1.05 -3.9%
7 COLL Collegium Pharmaceutical, Inc. 9.2 $33.37 -9.1%
8 TEVA Teva Pharmaceutical Industries 6.7 $34.52 -23.9%
9 HLN Haleon plc 9.0 $9.21 -24.0%
10 AMPH Amphastar Pharmaceuticals, Inc. 10.0 $19.30 -26.0%
11 Z••• Zoetis ••••• •.• $•••.•• ••.•%
12 C••• Cronos ••••• •.• $•••.•• ••.•%
13 E••• Evolus, ••••• •.• $•••.•• ••.•%
14 V••• Viatris ••••• •.• $•••.•• ••.•%
15 R••• Dr. ••••• •.• $•••.•• ••.•%
16 A••• ANI ••••• •.• $•••.•• ••.•%
17 L••• Lantheus ••••• •.• $•••.•• ••.•%
18 I••• Indivior ••••• •.• $•••.•• ••.•%
19 P••• Prestige ••••• •.• $•••.•• ••.•%
20 U••• United ••••• •.• $•••.•• ••.•%
🔒

Unlock the Full Best Earnings Power Value Drug Manufacturers - Specialty & Generic Stocks 2026 List

Screen all 44 Drug Manufacturers - Specialty & Generic stocks with 13 institutional-grade valuation models. Updated daily from SEC EDGAR filings.

Access Full Screening — From $27/mo →

How CirclFi Ranks Drug Manufacturers - Specialty & Generic Stocks

CirclFi analyzes 44 Drug Manufacturers - Specialty & Generic stocks daily using 13 independent institutional-grade valuation models. Each model processes SEC EDGAR 10-K and 10-Q financial filings (700+ XBRL tags), FRED macroeconomic data, and GDELT news sentiment.

The best earnings power value drug manufacturers - specialty & generic stocks 2026 ranking uses epv upside as the primary sort criterion. Models span intrinsic valuation (Bayesian DCF with 10,000 Monte Carlo simulations, EPV), scenario analysis (First Chicago), regime-switching (Markov DDM), and machine learning (ML-RIV, FTNN Topology).